Evidence map›Paper›PMID 40841152›Full record

ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2025

Evaluating Radiotheranostic Targets for Endometrial Cancer.

Joni Sebastiano, Shane A McGlone, Zachary V Samuels, Camilla Grimaldi, Ava Stoddard, Sugar Galka, Emma Colaco, Brian M Zeglis

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Joni SebastianoDepartment of Chemistry, Hunter College, City University of New York, New York, New York.
Shane A McGloneDepartment of Chemistry, Hunter College, City University of New York, New York, New York.
Zachary V SamuelsDepartment of Chemistry, Hunter College, City University of New York, New York, New York.
Camilla GrimaldiDepartment of Chemistry, Hunter College, City University of New York, New York, New York.
Ava StoddardDepartment of Chemistry, Hunter College, City University of New York, New York, New York.
Sugar GalkaDepartment of Chemistry, Hunter College, City University of New York, New York, New York.
Emma ColacoDepartment of Chemistry, Hunter College, City University of New York, New York, New York.
Brian M ZeglisDepartment of Chemistry, Hunter College, City University of New York, New York, New York; bz102@hunter.cuny.edu.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
Novel Transgenic Mouse Models Addressing Outstanding Translational Barriers in Antibody-Based TherapeuticsR01CA244327 · NCI · ROCKEFELLER UNIVERSITY · PI BOURNAZOS, STYLIANOS · 2020 to 2024
$3.0M
Autoantibodies to tumor-derived neoepitopes as biomarkers and immunoPET agents for the early detection of small cell lung cancerR01CA281801 · NCI · FRED HUTCHINSON CANCER CENTER · PI Delphine L Chen, PAUL D. LAMPE · 2023 to 2026
$2.4M
Novel Reagents for Rapid and Stable Thiol-Based BioconjugationsR01CA240963 · NCI · HUNTER COLLEGE · PI ZEGLIS, BRIAN MATTHEW · 2019 to 2023
$1.6M
Targeting DNA Mismatches for Auger Electron RadiotherapyR21CA280595 · NCI · HUNTER COLLEGE · PI HUMM, JOHN L, ZEGLIS, BRIAN MATTHEW · 2023 to 2023
$458k
NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA240963NCI NIH HHS R01 CA244327NCI NIH HHS R01 CA281801NCI NIH HHS R21 CA280595
6 · The paper itself

Abstract

Endometrial cancer is the most common gynecologic malignancy worldwide, and its incidence and mortality rates have increased over the past decade. Although early-stage disease is effectively treated via hysterectomy, a dearth of molecularly targeted therapies means that prognoses are far poorer for those with disseminated or recurrent disease. Herein, we describe the exploration of 3 biomarkers-human epidermal growth factor receptor 2 (HER2), mucin-16 (MUC16), and CD24-as potential radiotheranostic targets for endometrial cancer.

Indexed as

Endometrial NeoplasmsAnimalsBiomarkers, TumorCD24 AntigenCell Line, TumorErb-b2 Receptor Tyrosine KinasesFemaleHumansMiceMolecular Targeted TherapyRadioisotopesTissue DistributionZirconiumBiomarkers, TumorCD24 AntigenERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesRadioisotopesZirconiumZirconium-89CD24endometrial cancerHER2MUC16PETradiopharmaceuticals

Identifiers

PMID40841152
PMCPMC12487871

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.